Open Access Open Access  Restricted Access Subscription or Fee Access


Pathan Adiba M. Mansoor, Prajakta Nandkishor kelgaonkar, Akangksha Gajanan Ingole


Background: Polypharmacy, the concurrent use of multiple medications, has become a prevalent concern in healthcare systems worldwide. This prospective observational study aimed to assess the relative risk and incidence of polypharmacy while investigating its impact on patient outcomes and exploring strategies for minimizing its irrational use. Forms for complete case reports and informed permission were used in the data gathering procedure. The study had 68 individuals in all, including both males and females. Utilizing statistical tools various parameters were analyzed to evaluate the adverse effects of polypharmacy. Hepatic and renal abnormalities, adverse drug reactions, drug-drug interactions, and demographic factors were meticulously examined. Furthermore, medication adherence, patient history (both medical and social), and co-morbidities were assessed to provide a comprehensive understanding of polypharmacy's implications. By adopting a patient-centered approach, this study sought to improve the quality of life, reduce mortality and morbidity, and minimize irrational medication practices. The findings shed light on the critical role of clinical pharmacokinetic considerations in addressing the challenges associated with polypharmacy. Result: This study emphasizes the demand for efficient methods for controlling and preventing polypharmacy. Through the identification and understanding of associated risks and adverse effects, healthcare professionals can develop new approaches to reduce the prevalence of polypharmacy and enhance patient care. By optimizing medication regimens and fostering individualized treatment plans, healthcare providers can significantly mitigate the potential harm caused by polypharmacy and improve patient outcomes. Conclusion: Addressing the challenges posed by polypharmacy by employing a multidisciplinary approach that encompasses patient education, healthcare provider collaboration, and the development of evidence-based guidelines, can effectively minimize the occurrence of polypharmacy and optimize medication practices.


Polypharmacy, Adverse drug reaction, Case report, Irrational use, Co-morbidities.

Full Text:



.1 Kuhn-Thiel, A. M. Weiss, C., Webling, M., & Faller B. Polypharmacy in older patients: what is it and how can it be measured? Experimental gerontology. 2015:(69):10-9.

.L Hepler, C. D., & Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharmacy. 1990;3(47) 533-43.

.Maher, R. L. Hanlon, J. Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 1(13):57-65.

.Marcum, Z. A., & Hanlon JT. Recognizing the risks of polypharmacy in older adults. Clin Care Aging. 2010.9(18):33-68. [5].Patterson, S. M., Cadogan, C. A., Kerse, N., Cardwell, C. R., & Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. ((10).). [6].Becker, M. L., Kallewaard, M., Caspers, P. W., Visser, L. E., Leufkens, H. G., & Stricker BH. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharm world Sci. 2007;29(4):364-77.

.WM. L. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure.Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology. 2004;40(1):6-9.

.Pasina, L., Djade, C. D., Lucca, U., Nobili, A., Tettamanti, M., Franchi, C. & Mannucci PM. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs & aging. 2013;13(2):103-12

.National institute for health and care excellence. Medicine optimization; the safe and effective use of medicines to enable the best possible outcomes. [internet]. [cited 2023 apr27]. available from :

.Richardson, K., Bennett, K., & Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Drugs & aging. 2015;44(1):90-6.

. Kapoor, A., & Kapoor A. Prevalence of polypharmacy among elderly in India: systematic review. J Pharmacol Pharmacother. 2013:4(4):231-6.

. Tripathi, R. K., & Jalgaonkar S V. Prevalence of polypharmacy in a rural population in India: A cross-sectional study. Indian J Community Med. 2015;40(1):33-5

]. Gnjidic, D. Le Couteur, D. G., & Hilmer SN. Underutilisation of pharmacological treatment in older people. Drugs & aging, 2012:29(6):463-75. 8. Maher, R. L., Hanlon, J. T., & Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin drug safety. 2014;13(1):57-65.


  • There are currently no refbacks.

Copyright (c) 2023 Research & Reviews: A Journal of Pharmacology